Transforming Treatment of Advanced/Metastatic Cutaneous Squamous Cell Carcinoma: The Immune System and the Role of PD-1
OncologyTransforming Treatment of Advanced/Metastatic Cutaneous Squamous Cell Carcinoma
0.25 AMA PRA Category 1 Credit(s) ™
October 29, 2018
The accreditation for this activity has expired.
Primary Audience:
dermatologists, dermato-oncologists, Mohs surgeons, head and neck specialists, medical oncologists
Relevant Terms:
skin cancer, cutaneous squamous cell carcinoma, cSCC, PD-1, PD-1 inhibition
Omid Hamid, MD
Omid Hamid, MD
Chief, Translational Research & Immuno-Oncology
Director, Cutaneous Malignancies
The Angeles Clinic and Research Institute
Director of Experimental Therapeutics
Cedars Sinai Medical Care Foundation
Los Angeles, California
BioOmid Hamid MD is the Chief of Translational Research and Immuno-Oncology at The Angeles Clinic and Research Institute. He also serves as the Director of the Melanoma and Phase I Programs. His areas of expertise include immunotherapy and phase I drug development.
Dr. Hamid has published extensively and has been at the forefront of the development of paradigm shifting breakthroughs including BRAF/MEK targeted agents, AntiCTLA4, antiPD1 and PDL1 therapies. His current interests include new immunotherapeutic options for patients including bi-specific antibodies, Adoptive T cell Therapy, and oncolytic therapies with a focus on combinatorial approaches resulting in potentially greater patient benefit. Through his leadership The Angeles Clinic has fostered a program that combines expert clinical care with teaching and leading clinical research.
Dr. Hamid is recognized as one of the preeminent Immuno-Oncologists and melanoma specialists in the world.
“My research focus involves manipulation of a patient's immune system to attack cancer cells and maintain continuously elevated levels of immunity. Researchers have been studying the role the immune system can play in eradicating cancer for decades. Recent advances in immuno-oncologic therapeutics have provided lasting benefits to patients with few treatment options available. These therapies are not only a ‘breakthrough’ in cancer therapy - they have revolutionized the way we treat cancer. In order to optimally treat our patients we need to understand not only the novel mechanism of action of these therapeutics, including the ability of late response post progression – but also their novel toxicities. The future of these therapies are not just in single agents. We have seen the promise of higher and more durable response with combinations of these agents. Our role of researchers and clinicians will be to utilize these concepts along with the understanding of immuno-oncologic targets and the role of clinical trials in supporting this revolution.”
| 1. | Describe the fundamentals of the immune system and the role and rationale for PD-1 inhibition as a treatment option for cutaneous squamous cell carcinoma |
| 1. | Describe the fundamentals of the immune system and the role and rationale for PD-1 inhibition as a treatment option for cutaneous squamous cell carcinoma |
CONTINUING MEDICAL EDUCATION
Accreditation Statement
In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation for Physicians
AXIS Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™ for each component of the 3-part series. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AXIS Contact Information
For information about the certification of this activity, please contact AXIS at info@axismeded.com
Fee Information
There is no fee for this educational activity.
Method of Participation and Request for Credit
To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately.
Disclosure of Conflicts of Interest
AXIS Medical Education requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by AXIS for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
AXIS will identify, review, and resolve all conflicts of interestthat faculty, authors, activity directors, planners, managers, peer reviewers, or relevant staff disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. Disclosure information for speakers, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.
The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:
Omid Hamid, MD, reported a financial interest/relationship or affiliation in the form of Consultant, Amgen, Inc, Novartis Pharmaceuticals Corp, Roche, Bristol-Myers Squibb Co, Merck & Co, Inc; Contracted research, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Co, Celldex, Inc, Genentech, Inc, Immunocore, Incyte Corp, Merck & Co, Inc, Merck Serano, MedImmune, Novartis Pharmaceuticals Corp, Pfizer, Inc, Rinat, Roche; Speakers' bureau, Bristol-Myers Squibb Co, Genentech, Inc, Novartis Pharmaceuticals Corp, Amgen, Inc.
The planners and managers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:
The following AXIS planners and managers, Linda Gracie-King, MS; Jocelyn Timko, BS; Stephanie Sutphin, PharmD; and Emma Nichols, PhD state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest of any amount during the past 12 months. Chrysalyne D. Schmults, MD, MSCE, reported a financial interest/relationship or affiliation in the form of Research grant, Regeneron Pharmaceuticals, Inc., Genentech, Inc., Novartis Pharmaceuticals Corporation. Robert Mocharnuk, MD, reported a financial interest/relationship or affiliation in the form of Common stock: Merck.
Disclosure of Unlabeled Use
This educational activity may contain discussion of agents that are not approved for use by the FDA and/or investigational (“off-label”) uses of agents that are approved by the FDA. The planners of this activity do not recommend the use of any agent outside of its labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each agent for information on its approved indications, contraindications, warnings, and other, related information.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.
Provided by
COURSE VIEWING REQUIREMENTS
| Supported Browsers: Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8 and above Google Chrome 28.0+ for Windows, Mac OS, or Linux Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux Safari 6+ for Mac OSX 10.7 and above For video playback, install the latest version of Flash or Quicktime. | Supported Phones & Tablets: Android 4.0.3 and above iPhone/iPad with iOS 6.1 or above |
